Therefore, it seems plausible to speculate that mINDY might be an interesting target for the treatment of metabolic disease, such as obesity, non-alcoholic fatty liver disease and type 2 diabetes [48, 107, 108]. Here, SLC13A5 is linked to obesity due to melanocortin 4 receptor deficiency.